Gyre Therapeutics, Inc. (GYRE)
Gyre Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Gyre Therapeutics, Inc. (GYRE) is a Biotechnology company based in US with a market capitalization of $553.8M. Revenue grew 10.2% year-over-year and free cash flow was negative at -$180K. This page tracks GYRE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 579 employees · IPO Apr 12, 2006
Valuation
Valuation & price
$6.55as of May 17, 2026· -26.2% vs 52w high
134.4
P/E ratio
Latest-FY diluted EPS
5.22
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$553.8M
Market cap
10.2%
Revenue growth (YoY)
95.3%
Gross margin
-$180K
Free cash flow (USD)
-$51.5M
Net debt
Net cash position
5.0%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
9
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 8, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 16, 2026Filing
Director Appointments
- 8-K eventJul 15, 2026Filing
Financial Statements Audit
- FinancingJul 13, 2026Filing
Securities Registration
- Insider sellJun 22, 2026Filing
Insider Sell $69KYe Weiguo · Chief Operating Officer · $68.7K
- FinancingJun 22, 2026Filing
Securities Registration
- 8-K eventJun 16, 2026Filing
Annual Meeting Results
- Insider sellJun 15, 2026Filing
Insider Sell $17KYe Weiguo · Chief Operating Officer · $17.3K
- Insider sellJun 11, 2026Filing
Insider Sell $129KYe Weiguo · Chief Operating Officer · $128.9K
- Insider sellJun 8, 2026Filing
Insider Sell $219KYe Weiguo · Chief Operating Officer · $218.6K
- 8-K eventJun 2, 2026Filing
Forward-Looking Statements
Questions
Frequently asked questions
What is Gyre Therapeutics, Inc.'s market cap?
Gyre Therapeutics, Inc. (GYRE) has a market capitalization of $553.8M.
What is GYRE's P/E ratio?
GYRE trades at a price-to-earnings ratio of 134.4, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is GYRE's price-to-book (P/B) ratio?
GYRE trades at 5.22 times book value per share.
Are insiders buying GYRE stock?
SEC Form 4 filings show no open-market insider buys at Gyre Therapeutics, Inc. in the last 90 days (9 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.